← Back to Search

Web-Based End-of-Life Planning Tool for Cancer

N/A

Waitlist Available

Led By Megan J. Shen

Research Sponsored by Fred Hutchinson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 36 months

Awards & highlights

Study Summary

This trial is testing a web-based tool to help people with advanced cancer plan for end-of-life. The program includes medical, legal, financial, and emotional preparation. It is expected to reduce distress and improve end-of-life preparation.

Who is the study for?

This trial is for adults with advanced cancer, who have a life expectancy of less than 12 months and have undergone at least one round of chemotherapy. Participants must be able to use a computer or mobile device, give informed consent, and speak English fluently. Those severely cognitively impaired or too ill to complete interviews are excluded.Check my eligibility

What is being tested?

The study tests a web-based tool created with Peacefully, Inc., aimed at helping patients with advanced cancers plan for end-of-life. It covers medical wishes, legal estate planning, financial matters, legacy building, and emotional support to potentially ease distress and improve preparation.See study design

What are the potential side effects?

Since this intervention involves using an online tool rather than medication or invasive procedures, traditional physical side effects are not expected. However, users may experience emotional discomfort while engaging in end-of-life planning activities.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 36 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 36 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Accrual

Change in advance care planning engagement: completion of advance directives, from baseline to 12 weeks post-randomization

Change in advance care planning engagement: completion of advance directives, from baseline to 24 weeks post-randomization

+14 more

Secondary outcome measures

Change in comprehensive end-of-life planning, from baseline to 12 weeks post-randomization

Change in comprehensive end-of-life planning, from baseline to 24 weeks post-randomization

Change in comprehensive end-of-life planning, from baseline to 4 weeks post-randomization

+15 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Group I (Peacefully's)Experimental Treatment2 Interventions

Patients receive Peacefully's web-based tool to help with end-of-life planning on day 7.

Group II: Group II (standard of care)Active Control2 Interventions

Patients receive standard care.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Peacefully, Inc.UNKNOWN

Fred Hutchinson Cancer CenterLead Sponsor

556 Previous Clinical Trials

1,343,168 Total Patients Enrolled

National Institute of Nursing Research (NINR)NIH

579 Previous Clinical Trials

10,376,282 Total Patients Enrolled

Media Library

Web-Based Tool for End-of-Life Planning Clinical Trial Eligibility Overview. Trial Name: NCT05564468 — N/A

Blood Cancers Research Study Groups: Group II (standard of care), Group I (Peacefully's)

Blood Cancers Clinical Trial 2023: Web-Based Tool for End-of-Life Planning Highlights & Side Effects. Trial Name: NCT05564468 — N/A

Web-Based Tool for End-of-Life Planning 2023 Treatment Timeline for Medical Study. Trial Name: NCT05564468 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the projected results of this trial?

"This trial will be evaluated over the course of 36 months, with a primary goal to observe changes in advance care planning engagement. Secondary outcomes include alterations in comprehensive end-of-life preparation, psychological distress as measured by Hospital Anxiety and Depression Scale (HADS), and emotional wellbeing via Functional Assessment of Cancer Therapy-General (FACT-G) scale at 4 weeks post randomization."

Answered by AI

Is this clinical investigation currently accepting participants?

"A review of the clinicaltrials.gov webpage reveals that this trial is not enrolling any additional participants at this time; it was initially posted on March 1st 2023, and last modified on September 29th 2022. Nonetheless, there are still 2474 other studies actively recruiting patients across the globe."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Design and Testing of a Web-Based Tool for the Improvement of End-of-Life Planning in Patients With Advanced Cancer

2024. "Design and Testing of a Web-Based Tool for the Improvement of End-of-Life Planning in Patients With Advanced Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05564468.